Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic’s Prestige LP Joins LDR’s Mob-C In Two-Level Cervical Disc Competition

Executive Summary

The US FDA approved Medtronic's artificial disc based on results of a 397-patient trial showing more favorable outcomes with Prestige LP than anterior cervical discectomy and fusion.

You may also be interested in...

Zimmer Biomet Buys LDR To Boost Spine Revenue Growth

The world's second-largest orthopedic device firm, Zimmer Biomet, is making its biggest move since Zimmer and Biomet merged in 2015 with a $1bn acquisition of spine-device specialists LDR.

CLINICAL CORNER: Medtronic’s Prestige LP Cervical Disc; Biotronik’s Orsiro DES, More

Clinica’s Clinical Corner provides an update on the latest R&D news and developments in ongoing clinical trials of early-, late-stage and approved medical devices.

ANALYSIS: Boston bags four approvals in July

It may be coming up to the summer, but the volume of product approvals doesn’t seem to be slowing. A total of 66 passed Clinica’s news desk in July, up from 59 during the same period last year, and 61 in June.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts